Evaluating the cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for the treatment of type 2 diabetes in a Spanish setting

被引：0
|
作者：
Tucker, D. [1 ]
Valentine, W. J. [1 ]
Nielsen, S. [2 ]
Townsend, C. [2 ]
Kotchie, R. [3 ]
Scheijbeler, H. [3 ]
机构：
[1] IMS Hlth, Basel, Switzerland
[2] Novo Nordisk AS, Virum, Denmark
[3] IMS Hlth, London, England
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)64978-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A263 / A263
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China
    James L. Palmer
    Meaghan Gibbs
    Huib WKFH Scheijbeler
    Robert W. Kotchie
    Steffen Nielsen
    Jeremy White
    William J. Valentine
    [J]. Advances in Therapy, 2008, 25 : 752 - 774
  • [42] Cost-effectiveness of insulin aspart compared to human insulin in pregnant women with type 1 diabetes in the UK
    Lloyd, A.
    Townsend, C.
    Munro, V.
    Twena, N.
    Nielsen, S.
    Holman, A.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (03) : 599 - 605
  • [43] Long-term evaluation of the cost-effectiveness of biphasic insulin aspart 30 versus insulin glargine in poorly controlled patients with type 2 diabetes receiving oral antidiabetic agents
    Cobden, D
    Palmer, A
    Nicklasson, L
    Roze, S
    Garber, A
    [J]. DIABETOLOGIA, 2005, 48 : A336 - A336
  • [44] Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
    McCrimmon, Rory J.
    Palmer, Karen
    Alsaleh, Abdul Jabbar Omar
    Lew, Elisheva
    Puttanna, Amar
    [J]. DIABETES THERAPY, 2022, 13 (06) : 1203 - 1214
  • [45] Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
    Hui Shao
    Abdul Jabbar Omar Alsaleh
    Terry Dex
    Elisheva Lew
    Vivian Fonseca
    [J]. Diabetes Therapy, 2022, 13 : 1659 - 1670
  • [46] Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
    Shao, Hui
    Alsaleh, Abdul Jabbar Omar
    Dex, Terry
    Lew, Elisheva
    Fonseca, Vivian
    [J]. DIABETES THERAPY, 2022, 13 (09) : 1659 - 1670
  • [47] Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
    Valensi, Paul
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY, 2009, 2 : 61 - 71
  • [48] Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
    Rory J. McCrimmon
    Karen Palmer
    Abdul Jabbar Omar Alsaleh
    Elisheva Lew
    Amar Puttanna
    [J]. Diabetes Therapy, 2022, 13 : 1203 - 1214
  • [49] Biphasic insulin aspart in the treatment of type 2 diabetes mellitus
    Cucinotta, Domenico
    Russo, Giuseppina T.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (17) : 2905 - 2911
  • [50] Estimating the long term cost-effectiveness of biphasic insulin aspart plus metformin versus optimization of oral hypoglycemic agents in insulin-naive patients with type 2 diabetes in a US cost setting
    Minshall, ME
    Ray, JA
    Lammert, M
    Nicklasson, L
    Valentine, WJ
    [J]. DIABETOLOGIA, 2005, 48 : A335 - A335
12345